News: Eli Lilly

09.09.2010 | Business Wire: Anacor Pharmaceuticals Establishes Collaboration to Discover New Medicines for Animal Health | Business Wire

PALO ALTO, Calif.-(BUSINESS WIRE)-Anacor Pharmaceuticals today announced the establishment of a research agreement with Eli Lilly and Company to create and develop new therapeutics for animal health. The collaboration takes advantage of Anacor s boron chemistry platform and (…)

[Read article]

[Source: Business Wire]

02.09.2010 | NCBI PubMed: Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Abstract Objective: To identify reasons for discontinuation and continuation of antipsychotic medications in the treatment of schizophrenia from the patients' and their clinicians' perspectives. Research design and methods: Two measures were previously developed to assess the (…)

[Read article]

[Source: NCBI PubMed]

01.09.2010 | NCBI PubMed: Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia: Thirty-Six-Month Results From the European Schizophrenia Outpatient Health Outcomes Study.

The incidence of treatment-emergent extrapyramidal symptoms (EPSs) and tardive dyskinesia (TD) in schizophrenic patients, and the clinical characteristics associated with an increased risk of developing EPSs and TD were examined. Patients (N = 7728) in the 3-year, prospective, (…)

[Read article]

[Source: NCBI PubMed]

02.09.2010 | NCBI PubMed: Selective Reduction in the Sphingomyelin Content of Atherogenic Lipoproteins Inhibits Their Retention in Murine Aortas and the Subsequent Development of Atherosclerosis.

OBJECTIVE: To unravel the complex mechanisms of the sphingolipid de novo synthesis pathway by using the sphingomyelin (SM) synthase 2 (Sms2) gene knockout (KO) approach to test our hypothesis that selectively decreasing plasma lipoprotein SM can play an important role in (…)

[Read article]

[Source: NCBI PubMed]

09.09.2010 | BioSpace: Eli Lilly and Company (LLY) Invests $150 Million With Venture Firms Seeking New Drug Candidates

Bloomberg - Eli Lilly & Co. plans to invest as much as $150 million in three venture capital funds to aid development of new medicines, as the company faces generic competition next year to its top-selling antipsychotic drug.

[Read article]

[Source: BioSpace]

09.09.2010 | BioSpace: Anacor Pharmaceuticals, Inc., Eli Lilly and Company (LLY) in Animal Health Research Partnership

PALO ALTO, Calif., Sep 09, 2010 (BUSINESS WIRE) - Anacor Pharmaceuticals today announced the establishment of a research agreement with Eli Lilly and Company to create and develop new therapeutics for animal health. The collaboration takes advantage of Anacor's boron chemistry (…)

[Read article]

[Source: BioSpace]

26.08.2010 | NCBI PubMed: Comparison of Medication Adherence and Healthcare Costs between Duloxetine and Pregabalin Initiators among Patients with Fibromyalgia.

Abstract Objective: To examine and compare medication adherence and direct healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Methods: A retrospective analysis of commercially insured fibromyalgia patients aged 18 to 64 was conducted (…)

[Read article]

[Source: NCBI PubMed]

01.09.2010 | NCBI PubMed: European Neuroscience-Seventh Biennial FENS Forum.

The European Neuroscience-Seventh Biennial FENS Forum, held in Amsterdam, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on sodium channel inhibitors, ionotropic glutamate receptor (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | NCBI PubMed: Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.

Adherence to, and persistence with, treatments for osteoporosis are low. Adherence with teriparatide decreases over time. Higher copayments in the commercial/Medicare population were associated with worse persistence. Understanding factors such as prior screening, prior (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | NCBI PubMed: Toxicogenomics and cancer risk assessment: A framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.

In order to determine a threshold for nongenotoxic carcinogens, the traditional risk assessment approach has been to identify a mode of action (MOA) with a nonlinear dose-response. The dose-response for one or more key event(s) linked to the MOA for carcinogenicity allows a (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | NCBI PubMed: Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

BACKGROUND: Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by ABCB1, also known as MDR1). ABCB1 polymorphisms, particularly 3435C- T, may affect drug transport and efficacy. We aimed to assess the effect of this polymorphism by itself and alongside (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | NCBI PubMed: A{beta} Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model.

Senile plaques formed by beta-amyloid peptides (Abeta) and neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau, a microtubule-associated protein, are the hallmark lesions of Alzheimer's disease (AD) in addition to loss of neurons. While several transgenic (Tg) (…)

[Read article]

[Source: NCBI PubMed]

30.08.2010 | NCBI PubMed: Rasch Analysis of the Orientation Log and Reconsideration of the Latent Construct During Inpatient Rehabilitation.

PRIMARY OBJECTIVES: To investigate the measurement properties of the Orientation Log (O-Log) and a hybrid scale using Rasch analysis techniques and to explore the relations between the items of the 2 scales and the latent linear construct modeled in the Rasch analysis. (…)

[Read article]

[Source: NCBI PubMed]

30.08.2010 | NCBI PubMed: Safety and Resource Utilization by Non-small Cell Lung Cancer Histology: Results from the Randomized Phase III Study of Pemetrexed Plus Cisplatin versus Gemcitabine Plus Cisplatin in Chemonaïve Patients with Advanced Non-small Cell Lung Cancer.

INTRODUCTION: A prespecified analysis of the large, randomized, phase III study in advanced non-small cell lung cancer showed significant improvement in survival for nonsquamous patients treated with pemetrexed/cisplatin versus gemcitabine/cisplatin. Selected grade 3/4 (…)

[Read article]

[Source: NCBI PubMed]

07.09.2010 | BioSpace: Circadian Technologies Limited (CIR.AX) Granted Key Strategic VEGF-D Patent in USA for Diagnostic Applications

6 September 2010 - Circadian Technologies Limited (ASX:CIR) announced today that its subsidiary company, Vegenics Limited, has been granted US Patent 7785803 claiming diagnostic kits for the detection of VEGF-D in human samples such as blood. VEGF-D, a major novel target for (…)

[Read article]

[Source: BioSpace]

06.09.2010 | Business Wire: Research and Markets: Men's Health Therapeutics Market to 2016 - in-Depth Analysis of the Unmet Needs, Drivers & Barriers Affecting the Men's Health Market | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e3fec8/mens_health_thera) has announced the addition of the "Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and (…)

[Read article]

[Source: Business Wire]

06.09.2010 | Business Wire: Research and Markets: Women's Health Therapeutics, Analysis and Market Forecasts to 2016 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/61183d/womens_health_the) has announced the addition of the "Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in (…)

[Read article]

[Source: Business Wire]

06.09.2010 | Business Wire: Research and Markets: Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fe4133/urological_disorde) has announced the addition of the "Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic (…)

[Read article]

[Source: Business Wire]

02.09.2010 | Medical News Today: Trial To Test Experimental Drug For Advanced Pancreatic Cancer

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat. Around 60 patients with advanced pancreatic cancer will be recruited for (…)

[Read article]

[Source: Medical News Today]

02.09.2010 | Medical News Today: Actavis Receives FDA Approval Of Atomoxetine HCl Capsules

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD). Actavis intends to market Atomoxetine HCl in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg (…)

[Read article]

[Source: Medical News Today]

31.08.2010 | Business Wire: Research and Markets: Philippines Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/66a1b1/philippines_pharma) has announced the addition of the "Philippines Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Philippines Pharmaceuticals and (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Sun Pharma Announces USFDA Approval for Generic Strattera Capsules | Business Wire

MUMBAI, India-(BUSINESS WIRE)-Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of (…)

[Read article]

[Source: Business Wire]

31.08.2010 | Business Wire: Research and Markets: Poland Pharmaceuticals and Healthcare Report Q4 2010 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/46792f/poland_pharmaceuti) has announced the addition of the "Poland Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Poland Pharmaceuticals and Healthcare Report (…)

[Read article]

[Source: Business Wire]

31.08.2010 | BioSpace: Flagship Biosciences LLC Creates Scientific Advisory Board

Flagstaff, AZ (PRWEB) August 27, 2010 - Flagship Biosciences LLC, a provider of digital pathology services, has formed a Scientific Advisory Board composed of experienced leaders in the pharmaceutical industry. Flagship is a pathologist-owned company committed to improving the (…)

[Read article]

[Source: BioSpace]

30.08.2010 | Business Wire: Research and Markets: This Essential Analysis Examines the Historical and Forecast Performance for Eli Lilly In the Prescription Pharma Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/37adf0/eli_lilly_co_p) has announced the addition of the "Eli Lilly & Co.: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control Issues | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d141a8/strategies_for_man) has announced the addition of the "Strategies for Managing Pharmaceutical Workforce and Site Reductions: Analysis of Legal, Productivity, and Quality Control (…)

[Read article]

[Source: Business Wire]

30.08.2010 | Business Wire: Research and Markets: This Analysis Examines the Historical and Forecast Performance for Johnson & Johnson in the Ethical Pharmaceutical Sector | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/aabcf1/johnson_johnson) has announced the addition of the "Johnson & Johnson: PharmaVitae Profile" company profile to their offering. Introduction This analysis examines the historical and (…)

[Read article]

[Source: Business Wire]

28.08.2010 | Medical News Today: Sermo Report Indicates That Ticagrelor Is Likely To Affect The Standard Of Care For ACS Patients

Sermo, the world's largest online community for physicians, announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary (…)

[Read article]

[Source: Medical News Today]

27.08.2010 | Business Wire: Research and Markets: Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db0b08/type_2_diabetes) has announced the addition of GlobalData 's new report "Type 2 Diabetes - Pipeline Assessment and Market Forecasts to 2017" to their offering. Type 2 Diabetes - (…)

[Read article]

[Source: Business Wire]

27.08.2010 | Business Wire: Research and Markets: Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/883f56/novel_antibodies_a) has announced the addition of the "Novel Antibodies and Therapeutic Proteins - Technology Challenges and Future Prospects" report to their offering. Novel (…)

[Read article]

[Source: Business Wire]

26.08.2010 | NCBI PubMed: Factors Affecting the Chemical Durability of Glass Used in the Pharmaceutical Industry.

Delamination, or the generation of glass flakes in vials used to contain parenteral drug products, continues to be a persistent problem in the pharmaceutical industry. To understand all of the factors that might contribute to delamination, a statistical design of experiments (…)

[Read article]

[Source: NCBI PubMed]

27.08.2010 | BioSpace: Idera Pharmaceuticals, Inc. (IDRA) Achieves Clinical Milestone Under Its Collaboration with Merck KGaA (MKGAF.PK) for Cancer Treatment; Idera To Receive E3.0 Million (Approximately $3.8 Million)

CAMBRIDGE, Mass.-(BUSINESS WIRE)-Idera Pharmaceuticals, Inc. (Nasdaq: IDRA - News), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA s (…)

[Read article]

[Source: BioSpace]

27.08.2010 | BioSpace: Eli Lilly and Company (LLY) Wins Longer Halt Of Generic Strattera Sales

NEW YORK, Aug 27 (Reuters) - A federal appeals court has extended a temporary order blocking 10 companies from selling generic versions of Eli Lilly and Co's (LLY.N) Strattera attention deficit disorder drug.

[Read article]

[Source: BioSpace]

26.08.2010 | Medical News Today: Increased Generic Erosion Of Key Agents Such As Lamictal And Depakote/Depakote ER Will Cause A $2.3 Billion Decline In The Drug Market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the increased generic erosion of key drugs such as lamotrigine (GlaxoSmithKline's Lamictal, generics) and divalproex (Abbott/Sanofi-Aventis's (…)

[Read article]

[Source: Medical News Today]

26.08.2010 | Business Wire: Research and Markets: This Essential World Pharmaceutical Market Analysis Digest Guide with Forecasts Predicts the Market Will Stabilize the Years Up To 2014 | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e03d6e/world_pharmaceutic) has announced the addition of the "World Pharmaceutical Market Analysis - A Digest Guide, 2010-2014" report to their offering. World Pharmaceutical Market (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Genetically Modified Organisms (GMO) Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Genetically Modified Organisms research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not (…)

[Read article]

[Source: Business Wire]

25.08.2010 | Business Wire: Iroko Cardio International Sà rl Commences Operations and Appoints Dr. Jürgen Raths as President and CEO | Business Wire

GENEVA-(BUSINESS WIRE)-Dr. Jürgen Raths has been appointed President and CEO of Iroko Cardio International Sà rl, a newly created business entity focusing on the commercialization of Aggrastat (Tirofiban) world-wide outside the USA. Iroko Cardio International operates out (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Smoking Cessation Research Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Smoking Cessation research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Antibacterial Research Database | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Antibacterial research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Research and Markets: Online Healthcare Empowers Consumers - Healthcare Providers are Beginning to Offer Their Services Online | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/669c07/online_healthcare) has announced the addition of eMarketer's new report "Online Healthcare Empowers Consumers" to their offering. Healthcare consumers go online for an increasing (…)

[Read article]

[Source: Business Wire]

26.08.2010 | Business Wire: Maven Semantic: Tissue Banking Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Tissue Banking research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise (…)

[Read article]

[Source: Business Wire]

23.07.2010 | NCBI PubMed: Structure of a putative BenF-like porin from Pseudomonas fluorescens Pf-5 at 2.6 A resolution.

Proteins. |-| Sampathkumar P, Lu F, Zhao X, Li Z, Gilmore J, Bain K, Rutter ME, Gheyi T, Schwinn KD, Bonanno JB, Pieper U, Fajardo JE, Fiser A, Almo SC, Swaminathan S, Chance MR, Baker D, Atwell S, Thompson DA, Emtage JS, Wasserman SR, Sali A, Sauder JM, Burley SK. |-| New York (…)

[Read article]

[Source: NCBI PubMed]